Dynavax said that the candidate vaccine, DV-601, is designed to induce an immune response against HBV-infected cells and if proven to be safe and effective, may offer an alternative therapeutic option for patients chronically infected with HBV.
The dose escalation study evaluated the safety and the immunologic and virologic responses in 14 subjects with chronic hepatitis B infection.
The results from the Phase 1b trial suggested that the hepatitis B vaccine was well tolerated and individual immunologic and virologic responses were observed across cohorts at all the dose levels.